000272592 001__ 272592
000272592 005__ 20250127091449.0
000272592 0247_ $$2pmid$$apmid:39409066
000272592 0247_ $$2doi$$a10.3390/ijms251910737
000272592 0247_ $$2ISSN$$a1422-0067
000272592 0247_ $$2ISSN$$a1661-6596
000272592 0247_ $$2pmc$$apmc:PMC11476365
000272592 037__ $$aDZNE-2024-01213
000272592 082__ $$a540
000272592 1001_ $$0P:(DE-2719)9000370$$aFischer, Thomas$$b0
000272592 245__ $$aTumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [131I]-Iodine-ERIC1 in Neuroblastoma-Bearing Mice
000272592 260__ $$aBasel$$bMolecular Diversity Preservation International$$c2024
000272592 3367_ $$2DRIVER$$aarticle
000272592 3367_ $$2DataCite$$aOutput Types/Journal article
000272592 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1729175535_2185
000272592 3367_ $$2BibTeX$$aARTICLE
000272592 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000272592 3367_ $$00$$2EndNote$$aJournal Article
000272592 520__ $$a Preliminary studies on a radioactive antibody against the neural cell adhesion molecule (NCAM) demonstrated a significant accumulation of [131I]I-ERIC1 in neuroblastoma tumor cells in mice. This study aims to validate the therapeutic efficacy and potential adverse effects of these radioactive immunoconjugates (RICs) in neuroblastoma-bearing mice. To determine the highest tolerated dose, healthy SCID mice received 1 to 22 MBq of [131I]I-ERIC1, with the survival time measured. Tumor response was evaluated by administering 0.8 to 22 MBq of [131I]I-ERIC1 to neuroblastoma-bearing mice and assessing tumor size and systemic toxicity through body weight, blood counts, and survival. It was observed that doses up to approximately 3 MBq per animal (150 MBq/kg) were well tolerated, whereas higher doses resulted in systemic toxicity and death. The neuroblastomas exhibited a dose-dependent response, with optimal therapeutic efficacy achieved at 1.8-2.5 MBq per animal (90-125 MBq/kg), significantly extending survival by a factor of five. The antibody ERIC1 is a promising vehicle for the transport of beta emitters into NCAM-positive tumor tissue. An optimal dosage of the [131I]I-ERIC1 antibody can be established with a balance of tumor-static effects and adverse effects, resulting in a marked extension of survival time.
000272592 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000272592 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000272592 650_2 $$2MeSH$$aAnimals
000272592 650_2 $$2MeSH$$aNeuroblastoma: pathology
000272592 650_2 $$2MeSH$$aNeuroblastoma: metabolism
000272592 650_2 $$2MeSH$$aNeuroblastoma: drug therapy
000272592 650_2 $$2MeSH$$aMice
000272592 650_2 $$2MeSH$$aIodine Radioisotopes: adverse effects
000272592 650_2 $$2MeSH$$aCell Line, Tumor
000272592 650_2 $$2MeSH$$aNeural Cell Adhesion Molecules: metabolism
000272592 650_2 $$2MeSH$$aHumans
000272592 650_2 $$2MeSH$$aMice, SCID
000272592 650_2 $$2MeSH$$aXenograft Model Antitumor Assays
000272592 650_2 $$2MeSH$$aImmunoconjugates: pharmacology
000272592 650_2 $$2MeSH$$aFemale
000272592 650_2 $$2MeSH$$aAntibodies, Monoclonal: therapeutic use
000272592 650_2 $$2MeSH$$aAntibodies, Monoclonal: pharmacology
000272592 7001_ $$00000-0002-6651-7155$$aDietlein, Felix$$b1
000272592 7001_ $$aBongartz, Detlev$$b2
000272592 7001_ $$aKlehr, Martin$$b3
000272592 7001_ $$00009-0009-2207-9657$$aZimmermanns, Beate$$b4
000272592 7001_ $$00000-0002-7519-8897$$aSchmidt, Matthias$$b5
000272592 7001_ $$aMohr, Angela$$b6
000272592 7001_ $$00000-0001-7272-935X$$aMohr, Fabian$$b7
000272592 7001_ $$aSudbrock, Ferdinand$$b8
000272592 7001_ $$aKrapf, Philipp$$b9
000272592 7001_ $$0P:(DE-2719)2811239$$aDrzezga, Alexander$$b10$$udzne
000272592 7001_ $$00000-0003-0992-6099$$aDietlein, Markus$$b11
000272592 7001_ $$aSchomäcker, Klaus$$b12
000272592 770__ $$aMonoclonal Antibodies and Their Functional Fragments in Research, Diagnosis and Therapy 3.0
000272592 773__ $$0PERI:(DE-600)2019364-6$$a10.3390/ijms251910737$$gVol. 25, no. 19, p. 10737 -$$n19$$p10737$$tInternational journal of molecular sciences$$v25$$x1422-0067$$y2024
000272592 8564_ $$uhttps://pub.dzne.de/record/272592/files/DZNE-2024-01213.pdf$$yOpenAccess
000272592 8564_ $$uhttps://pub.dzne.de/record/272592/files/DZNE-2024-01213.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000272592 909CO $$ooai:pub.dzne.de:272592$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000272592 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811239$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000272592 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000272592 9141_ $$y2024
000272592 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000272592 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000272592 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000272592 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
000272592 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J MOL SCI : 2022$$d2023-08-25
000272592 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J MOL SCI : 2022$$d2023-08-25
000272592 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-07T16:31:47Z
000272592 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-07T16:31:47Z
000272592 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000272592 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-25
000272592 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000272592 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000272592 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
000272592 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-25
000272592 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-08-25
000272592 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000272592 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000272592 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000272592 9201_ $$0I:(DE-2719)1011202$$kAG Boecker$$lPositron Emissions Tomography (PET)$$x0
000272592 980__ $$ajournal
000272592 980__ $$aVDB
000272592 980__ $$aUNRESTRICTED
000272592 980__ $$aI:(DE-2719)1011202
000272592 9801_ $$aFullTexts